Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Landscape of Prostate Tumour Methylation.

Cancer discovery·2026
Same author

A Multidisciplinary Approach to Prevention and Treatment of Late Genitourinary Adverse Events After Radiotherapy for Prostate Cancer.

European urology·2026
Same author

Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

Cancer discovery·2026
Same author

Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis.

JAMA oncology·2026

Related Experiment Video

Updated: Jun 26, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.

Thomas W Flaig1, Philippe E Spiess2, Michael Abern3

  • 11University of Colorado Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 16, 2024
PubMed
Summary
This summary is machine-generated.

Updates to bladder cancer guidelines include new classifications and treatments for non-muscle-invasive bladder cancer (NMIBC) and advanced stages. These insights address BCG-unresponsive NMIBC and systemic therapy changes for metastatic disease.

More Related Videos

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.3K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.6K

Related Experiment Videos

Last Updated: Jun 26, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.3K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.6K

Area of Science:

  • Oncology
  • Urology

Background:

  • Bladder cancer, predominantly urothelial carcinoma, presents a clinical spectrum divided into non-muscle-invasive (NMIBC), muscle-invasive, and metastatic disease.
  • Each category requires distinct management strategies and therapeutic goals based on prognosis.

Purpose of the Study:

  • To detail recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer.
  • To incorporate changes from the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours.
  • To outline emerging treatments for bacillus Calmette-Guérin (BCG)-unresponsive NMIBC and revised systemic therapy recommendations for advanced/metastatic bladder cancer.

Main Methods:

  • Review and synthesis of updated NCCN Guidelines for Bladder Cancer.
  • Alignment of guidelines with the latest WHO tumor classification.
  • Inclusion of new therapeutic options for specific bladder cancer subtypes.

Main Results:

  • NCCN Guidelines have been updated to reflect the fifth edition of the WHO Classification of Tumours.
  • New treatment options are now available for patients with BCG-unresponsive NMIBC.
  • Systemic therapy recommendations for advanced or metastatic bladder cancer have been revised.

Conclusions:

  • The updated NCCN Guidelines provide current evidence-based recommendations for bladder cancer management.
  • Advances in classification and treatment offer improved therapeutic strategies for NMIBC and metastatic disease.
  • These insights facilitate optimal clinical decision-making for bladder cancer patients.